Hareth Nahi
Impact in
- Hematology top 0.5%
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
- Oncology top 2%
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
Papers in
- Hematology 124
- Multiple Myeloma Research and Treatments 106
- Acute Myeloid Leukemia Research 16
- Oncology 77
- Peptidase Inhibition and Analysis 33
- Cancer Treatment and Pharmacology 19
- CAR-T cell therapy research 9
- Co-authors
- Evren AliciGösta GahrtonTorben PlesnerChrister PaulSaad Z. UsmaniPaul G. RichardsonHenk M. LokhorstTolga Sütlü
- Journals
- Blood (28 papers)Journal of Clinical Oncology (14 papers)European Journal Of Haematology (14 papers)British Journal of Haematology (6 papers)Haematologica (4 papers)
- Partner nations
- SwedenUnited StatesSpain
In The Last Decade
Hareth Nahi
141 papers receiving 3.0k citations
Hit Papers
Peers
Comparison fields: 5 of 95
- Hematology 2.0k
- Oncology 1.5k
- Genetics 437
- Immunology 559
- Molecular Biology 1.6k
Countries citing papers authored by Hareth Nahi
This map shows the geographic impact of Hareth Nahi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hareth Nahi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hareth Nahi more than expected).
Fields of papers citing papers by Hareth Nahi
This network shows the impact of papers produced by Hareth Nahi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hareth Nahi. The network helps show where Hareth Nahi may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hareth Nahi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 5 | |
| 2 | 2024 | 0 | |
| 3 | 2023 | 2 | |
| 4 | 2023 | 2 | |
| 5 | 2022 | 3 | |
| 6 | 2021 | 2 | |
| 7 | 2020 | 5 | |
| 8 | 2020 | 12 | |
| 9 | 2019 | 22 | |
| 10 | 2019 | 7 | |
| 11 | 2018 | 58 | |
| 12 | 2017 | 8 | |
| 13 | 2016 | 1 | |
| 14 | 2016 | 13 | |
| 15 | An open-label, randomised phase 3 study of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): POLLUX | 2016 | 11 |
| 16 | 2015 | 42 | |
| 17 | 2013 | 4 | |
| 18 | 2012 | 41 | |
| 19 | 2009 | 4 | |
| 20 | 2008 | 26 |
About Hareth Nahi
Hareth Nahi is a scholar working on Hematology, Oncology, Genetics, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 143 papers that have together received 3.0k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (106 papers), Peptidase Inhibition and Analysis (33 papers), Protein Degradation and Inhibitors (33 papers), Monoclonal and Polyclonal Antibodies Research (22 papers), Cancer Treatment and Pharmacology (19 papers), Chronic Lymphocytic Leukemia Research (17 papers), Acute Myeloid Leukemia Research (16 papers) and CAR-T cell therapy research (9 papers). The work is most often cited by research in Hematology (2.0k citations), Oncology (1.5k citations), Genetics (437 citations), Immunology (559 citations) and Molecular Biology (1.6k citations). Hareth Nahi has collaborated with scholars based in Sweden, United States and Spain. Frequent co-authors include Evren Alici, Gösta Gahrton, Torben Plesner, Christer Paul, Saad Z. Usmani, Paul G. Richardson, Henk M. Lokhorst, Tolga Sütlü, Sören Lehmann and Per Ljungman. Their work appears in journals such as Blood, Journal of Clinical Oncology, European Journal Of Haematology, British Journal of Haematology and Haematologica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.